Stock HOLX HOLOGIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hologic, Inc.

Equities

HOLX

US4364401012

Real-time Estimate Cboe BZX
Other stock markets
 01:48:42 2024-04-25 pm EDT 		5-day change 1st Jan Change
75.98 USD -0.95% Intraday chart for Hologic, Inc. +0.83% +5.98%
Apr. 11 Bayer and Hologic Collaborates to Deliver Contrast-Enhanced Mammography CI
Apr. 09 Transcript : Hologic, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 11:45 AM

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The firm trades with high earnings multiples: 22.98 times its 2024 earnings per share.
  • The company's enterprise value to sales, at 4.33 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
HOLOGIC, INC. Stock Hologic, Inc.
+5.98% 18.01B
B+
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.75% 220B
B
DANAHER CORPORATION Stock Danaher Corporation
+6.72% 185B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+10.39% 133B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.62% 107B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-0.57% 62.91B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+15.78% 53.34B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-1.89% 47.71B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-2.27% 40.29B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+9.96% 39.57B -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. HOLX Stock
  4. Ratings Hologic, Inc.